Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease
Prashant Kapoor, Meletios A Dimopoulos, Stephen M. Ansell, Efstathios Kastritis, Ranjana H. Advani, Éric Durot, Pierre Morel, Charalampia Kyriakou, Roman Hájek, Daniela Drandi, Jithma P. Abeykoon, Signy Chow, Xinxin Cao, Christopher J. Patterson, Jeffrey Matous, Christian Buske, Steven P. Treon, Marie José Kersten (2025). Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease. , 62(2), DOI: https://doi.org/10.1053/j.seminhematol.2025.04.001.
Article38 days agoP-169: Bendamustine rituximab primary therapy for Waldenström Macroglobulinemia: an international, multicenter collaborative study
Saurabh Zanwar, Jithma P. Abeykoon, Jorge J. Castillo, Éric Durot, Efstathios Kastritis, Encarl Uppal, P. Morel, Reema Tawfiq, Lydia Montes, Jonas Paludo, Shayna Saroseik, Shaji Kumar, Olabisi Ogunbiyi, Pascale Cornillet‐Lefèbvre, Robert A. Kyle, Alain Delmer, Morie A. Gertz, Meletios A Dimopoulos, Stephen M. Ansell, Steven P. Treon, Shirley D’Sa, Prashant Kapoor (2022). P-169: Bendamustine rituximab primary therapy for Waldenström Macroglobulinemia: an international, multicenter collaborative study. , 22, DOI: https://doi.org/10.1016/s2152-2650(22)00499-2.
Article38 days agoBendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study.
Jithma P. Abeykoon, Shaji Kumar, Jorge J. Castillo, Shirley D’Sa, Efstathios Kastritis, Éric Durot, Encarl Uppal, Pierre Morel, Jonas Paludo, Reema Tawfiq, Shayna Sarosiek, Olabisi Ogunbiyi, Pascale Cornillet‐Lefèbvre, Robert A. Kyle, Alain Delmer, Morie A. Gertz, Meletios A Dimopoulos, Steven P. Treon, Stephen M. Ansell, Prashant Kapoor (2022). Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study.. , 40(16_suppl), DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.7566.
Article38 days agoProgression risk stratification of Asymptomatic Waldenström Macroglobulinemia
Romanos Sklavenitis‐Pistofidis, Mark Bustoros, Prashant Kapoor, Chia-Jen Liu, Efstathios Kastritis, Saurabh Zanwar, Geoffrey Fell, Jithma P. Abeykoon, Kalvis Hornburg, Carl Jannes Neuse, Catherine R. Marinac, David Liu, Jenny Soiffer, Maria Gavriatopoulou, Cody J. Boehner, Joseph M. Cappuccio, Henry Dumke, Kaitlen Reyes, Robert J. Soiffer, Robert A. Kyle, Steven P. Treon, Jorge J. Castillo, Meletios A Dimopoulos, Stephen M. Ansell, Lorenzo Trippa, Irene M. Ghobrial (2019). Progression risk stratification of Asymptomatic Waldenström Macroglobulinemia. , 19(10), DOI: https://doi.org/10.1016/j.clml.2019.09.058.
Article38 days agoProgression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia
Mark Bustoros, Romanos Sklavenitis‐Pistofidis, Prashant Kapoor, Chia‐Jen Liu, Efstathios Kastritis, Saurabh Zanwar, Geoffrey Fell, Jithma P. Abeykoon, Kalvis Hornburg, Carl Jannes Neuse, Catherine R. Marinac, David Liu, Jenny Soiffer, Maria Gavriatopoulou, Cody J. Boehner, Joseph M. Cappuccio, Henry Dumke, Kaitlen Reyes, Robert J. Soiffer, Robert A. Kyle, Steven P. Treon, Jorge J. Castillo, Meletios A Dimopoulos, Stephen M. Ansell, Lorenzo Trippa, Irene M. Ghobrial (2019). Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. , 37(16), DOI: https://doi.org/10.1200/jco.19.00394.
Article38 days ago